Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03099486 · ClinicalTrials.gov registry record · Phase 2
Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03099486 is a Phase 2 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 2 participants.
The verdict
NCT03099486, a Phase 2 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a single arm open label pilot phase II trial of Regorafenib PO plus 5-FU/LV infusion in 15 mCRC patients who progressed on prior Regorafenib monotherapy as well as 5-FU containing chemotherapy combinations.The study will enroll mCRC patients with prior progression on standard multi-agent combination chemotherapy and progression on regorafenib monotherapy.
Interventions
- DRUG Leucovorin
- DRUG Regorafenib
- DRUG 5-FU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-10-06 |
| Est. Completion | 2020-06-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03099486
The ClinicalTrials.gov registry entry for NCT03099486 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Leucovorin is the first listed.
NCT03099486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03099486 about?
NCT03099486 is a clinical study titled "Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC". This is a single arm open label pilot phase II trial of Regorafenib PO plus 5-FU/LV infusion in 15 mCRC patients who progressed on prior Regorafenib monotherapy as well as 5-FU containing chemotherapy combinations.The study will enroll mCRC patients with prior progression on standard multi-agent com...
What is the current status of trial NCT03099486?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2017-10-06. Estimated completion is 2020-06-02.
What interventions are being tested in trial NCT03099486?
The interventions under investigation include: Leucovorin (DRUG), Regorafenib (DRUG), 5-FU (DRUG).
Who is sponsoring clinical trial NCT03099486?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.